TMDX241220C82500
- 0.40
- +0.10+33.33%
TransMedics Newsroom
Piper Sandler Maintains TransMedics(TMDX.US) With Buy Rating, Cuts Target Price to $90
Oppenheimer Maintains TransMedics(TMDX.US) With Buy Rating, Maintains Target Price $125
TransMedics Group Is Maintained at Overweight by Piper Sandler
A Quick Look at Today's Ratings for TransMedics(TMDX.US), With a Forecast Between $90 to $120
TransMedics Group (TMDX) Gets a Buy From Oppenheimer
TransMedics Gr Analyst Ratings
CCORF Maintains TransMedics(TMDX.US) With Buy Rating, Maintains Target Price $104
Piper Sandler Maintains TransMedics(TMDX.US) With Buy Rating, Maintains Target Price $110
A Quick Look at Today's Ratings for TransMedics(TMDX.US), With a Forecast Between $104 to $120
Analysts Offer Insights on Healthcare Companies: Apogee Therapeutics, Inc. (APGE) and TransMedics Group (TMDX)
TransMedics Gr Analyst Ratings
TransMedics' Positive Trajectory: Buy Rating Reinforced by Growth in Heart and Lung Transplants
Needham Downgrades TransMedics(TMDX.US) to Hold Rating
Needham Downgrades TransMedics Gr to Hold, Maintains Price Target to $109
Oppenheimer Maintains TransMedics(TMDX.US) With Buy Rating, Cuts Target Price to $125
TransMedics Group (TMDX) Gets a Buy From Oppenheimer
TransMedics Group Is Maintained at Buy by Canaccord Genuity
TransMedics Group Price Target Cut to $104.00/Share From $109.00 by Canaccord Genuity
CCORF Maintains TransMedics(TMDX.US) With Buy Rating, Cuts Target Price to $104
Piper Sandler Maintains TransMedics(TMDX.US) With Buy Rating, Cuts Target Price to $110